Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa

Diagnostic Microbiology and Infectious Disease

Volumn 54, Issue 1, 2006, Pages 51-56

  Garrison, Mark W ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Deaconess Medical Center Spokane   (United States)

Author keywords

Ciprofloxacin; Gatifloxacin; High dose levofloxacin; P. aeruginosa; Pharmacodynamics

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; QUINOLONE;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG MEGADOSE; INOCULATION; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DNA, BACTERIAL; EVALUATION STUDIES; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PSEUDOMONAS AERUGINOSA;

EID: 29144434646     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.08.010     Document Type: Article

References (29)

1. A. Bauernfeind Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin J. Antimicrob. Chemother. 40 1997 639 651
2. S.M. Bhavnani, W.A. Callen, A. Forrest, K.K. Gilliland, D.A. Collins, J.A. Paladino, and J.J. Schentag Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals Am. J. Health Syst. Pharm. 60 2003 1962 1970
3. J. Blaser, B.B. Stone, M.C. Groner, and S.H. Zinner Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine the importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance Antimicrob. Agents Chemother. 31 1987 1054 1060
4. D.S. Burgess, R.G. Hall, and T.C. Hardin In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa Diagn. Microbiol. Infect. Dis. 46 2003 131 137
5. K. Chaplin-Robertson, and S.C. Edberg Measurements of antibiotics in human body fluids: techniques and significance V. Lorian Antibiotics in laboratory medicine 3rd ed. 1991 Williams and Wilkins Baltimore, MD 313
6. A.T. Chow, C. Fowler, R.R. Williams, N. Morgan, S. Kaminski, and J. Natarajan Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers Antimicrob. Agents Chemother. 45 2001 2122 2125
7. G.L. Drusano, S.L. Preston, C. Fowler, M. Corrado, B. Weisinger, and J. Kahn Relationship between fluoroquinolone area under the curve: minimal inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia J. Infect. Dis. 189 2004 1590 1597
8. M.N. Dudley, H.D. Mandler, D. Gilbert, J. Ericson, K.H. Mayer, and S.H. Zinner Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin: studies in vivo and in an vitro dynamic model Am. J. Med. 82 Suppl 4A 1987 363 368
9. L.M. Dunbar, R.G. Wunderink, M.P. Habib, L.G. Smith, A.M. Tennenberg, M.M. Khashab, B.A. Wiesinger, J.X. Xiang, N. Zadeikis, and J.B. Kahn High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm Clin. Infect. Dis. 37 2003 752 760
10. A. Forrest, D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob. Agents Chemother. 37 1993 1073 1081
11. S.K. Fridkin, H.A. Hill, N.V. Volkova, J.R. Edwards, R.M. Lawton, R.P. Gaynes, J.E. McGowan and the Intensive Care Antimicrobial resistance Epidemiology (ICARE) Project Hospitals Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals Emerg. Infect. Dis. 8 2002 697 701
12. I. Friedland, G. Gallagher, T. King, and G.L. Woods Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter intensive care unit surveillance study (ISS) in the United States J. Chemother. 16 2004 437 441
13. M.W. Garrison Comparative activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae J. Antimicrob. Chemother. 52 2003 503 506
14. M.W. Garrison, J.A. Schimmels, and K.J. Madaras-Kelly In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV Diagn. Microbiol. Infect. Dis. 47 2003 587 593
15. M. Gonzalez, A. Moranchel, and S. Duran Multi-dose pharmacokinetics of ciprofloxacin administered intravenously to healthy volunteers Antimicrob. Agents Chemother. 28 1985 235 239
16. R.N. Jones, and L.A. Mandell Fluoroquinolones for the treatment of outpatient community-acquired pneumonia Diagn. Microbiol. Infect. Dis. 44 2002 69 76
17. J.A. Karlowsky, D.C. Draghi, M.E. Jones, C. Thornsberry, I.R. Freidland, and D.F. Sahm Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998-2001 Antimicrob. Agents Chemother. 47 2003 1681 1688
18. J.A. Korvick, and V.L. Yu Antimicrobial agent therapy for Pseudomonas aeruginosa Antimicrob. Agents Chemother. 35 1991 2167 2172
19. J.L. Kuti, C.H. Nightingale, and D.P. Nicolau Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002 Antimicrob. Agents Chemother. 48 2004 2464 2470
20. M.K. Lacy, W. Lu, X. Xu, P.R. Tessier, D.P. Nicolau, R. Quintiliani, and C.H. Nightingale Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection Antimicrob. Agents Chemother. 43 1999 672 677
21. P.D. Lister, and C.C. Sanders Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae J. Antimicrob. Chemother. 43 1999 79 86
22. A.P. MacGowan, M. Wootton, and H.A. Holt The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility J. Antimicrob. Chemother. 43 1999 345 349
23. K.J. Madaras-Kelly, B.E. Ostergaard, L.B. Hovde, and J.C. Rotschafer Twenty-four hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model Antimicrob. Agents Chemother. 40 1996 627 632
24. L.A. Mandell, J.G. Bartlett, S.F. Dowell, T.M. File, D.M. Musher, and C. Whitney Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults Clin. Infect. Dis. 37 2003 1405 1433
25. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 6th ed. 2003 NCCLS Wayne, PA (Approved standard NCCLS Document M7-A6, Vol 23, No 2)
26. M.M. Neuhauser, R.A. Weinstein, R. Rydman, L.H. Danziger, G. Karam, and J.P. Quinn Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use JAMA 289 2003 885 888
27. K.V.I. Rolston, S. Frisbee-Hume, B. LeBlanc, H. Streeter, and D.H. Ho In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients Diagn. Microbiol. Infect. Dis. 47 2003 441 449
28. Tequin® (gatifloxacin tablets and injection) Gatifloxacin tablets/injection package insert. Bristol-Myers Squibb Company. Princeton, NJ 08543 (revised November 2004).
29. M. West, B.R. Boulanger, C. Fogarty, A. Tennenberg, B. Wiesinger, M. Oross, S.C. Wu, C. Fowler, N. Morgan, and J.B. Kahn Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized open-label study Clin. Ther. 25 2003 485 506